Literature DB >> 28729240

Empiric Antibiotic Use and Susceptibility in Infants With Bacterial Infections: A Multicenter Retrospective Cohort Study.

Elana A Feldman1, Russell J McCulloh2, Angela L Myers2, Paul L Aronson3, Mark I Neuman4, Miranda C Bradford5, Elizabeth R Alpern6, Frances Balamuth7, Mercedes M Blackstone7, Whitney L Browning8, Katie Hayes7, Rosalynne Korman8, Rianna C Leazer9, Lise E Nigrovic4, Richard Marble6, Emily Roben6, Derek J Williams8, Joel S Tieder5,10.   

Abstract

OBJECTIVES: To assess hospital differences in empirical antibiotic use, bacterial epidemiology, and antimicrobial susceptibility for common antibiotic regimens among young infants with urinary tract infection (UTI), bacteremia, or bacterial meningitis.
METHODS: We reviewed medical records from infants <90 days old presenting to 8 US children's hospitals with UTI, bacteremia, or meningitis. We used the Pediatric Health Information System database to identify cases and empirical antibiotic use and medical record review to determine infection, pathogen, and antimicrobial susceptibility patterns. We compared hospital-level differences in antimicrobial use, pathogen, infection site, and antimicrobial susceptibility.
RESULTS: We identified 470 infants with bacterial infections: 362 (77%) with UTI alone and 108 (23%) with meningitis or bacteremia. Infection type did not differ across hospitals (P = .85). Empirical antibiotic use varied across hospitals (P < .01), although antimicrobial susceptibility patterns for common empirical regimens were similar. A third-generation cephalosporin would have empirically treated 90% of all ages, 89% in 7- to 28-day-olds, and 91% in 29- to 89-day-olds. The addition of ampicillin would have improved coverage in only 4 cases of bacteremia and meningitis. Ampicillin plus gentamicin would have treated 95%, 89%, and 97% in these age groups, respectively.
CONCLUSIONS: Empirical antibiotic use differed across regionally diverse US children's hospitals in infants <90 days old with UTI, bacteremia, or meningitis. Antimicrobial susceptibility to common antibiotic regimens was similar across hospitals, and adding ampicillin to a third-generation cephalosporin minimally improves coverage. Our findings support incorporating empirical antibiotic recommendations into national guidelines for infants with suspected bacterial infection.
Copyright © 2017 by the American Academy of Pediatrics.

Entities:  

Year:  2017        PMID: 28729240      PMCID: PMC5525435          DOI: 10.1542/hpeds.2016-0162

Source DB:  PubMed          Journal:  Hosp Pediatr        ISSN: 2154-1671


  26 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  Empiric Antibiotics for Serious Bacterial Infection in Young Infants: Opportunities for Stewardship.

Authors:  Joseph B Cantey; Eduardo Lopez-Medina; Sean Nguyen; Christopher Doern; Carla Garcia
Journal:  Pediatr Emerg Care       Date:  2015-08       Impact factor: 1.454

3.  Association of clinical practice guidelines with emergency department management of febrile infants ≤56 days of age.

Authors:  Paul L Aronson; Cary Thurm; Derek J Williams; Lise E Nigrovic; Elizabeth R Alpern; Joel S Tieder; Samir S Shah; Russell J McCulloh; Fran Balamuth; Amanda C Schondelmeyer; Evaline A Alessandrini; Whitney L Browning; Angela L Myers; Mark I Neuman
Journal:  J Hosp Med       Date:  2015-02-13       Impact factor: 2.960

Review 4.  A Meta-analysis of the Rates of Listeria monocytogenes and Enterococcus in Febrile Infants.

Authors:  Rianna Leazer; Amy M Perkins; Kyrie Shomaker; Bryan Fine
Journal:  Hosp Pediatr       Date:  2016-01-01

5.  An examination of the unintended consequences of the rule-out sepsis evaluation: a parental perspective.

Authors:  R D Paxton; C L Byington
Journal:  Clin Pediatr (Phila)       Date:  2001-02       Impact factor: 1.168

6.  Epidemiology and laboratory diagnosis of infection with viral and bacterial pathogens in infants hospitalized for suspected sepsis.

Authors:  R Dagan; C B Hall; K R Powell; M A Menegus
Journal:  J Pediatr       Date:  1989-09       Impact factor: 4.406

7.  The changing epidemiology of serious bacterial infections in young infants.

Authors:  Tara L Greenhow; Yun-Yi Hung; Arnd M Herz; Elizabeth Losada; Robert H Pantell
Journal:  Pediatr Infect Dis J       Date:  2014-06       Impact factor: 2.129

Review 8.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

9.  Variation in emergency department diagnostic testing and disposition outcomes in pneumonia.

Authors:  Todd A Florin; Benjamin French; Joseph J Zorc; Elizabeth R Alpern; Samir S Shah
Journal:  Pediatrics       Date:  2013-07-22       Impact factor: 7.124

10.  Serious bacterial infections in febrile infants 1 to 90 days old with and without viral infections.

Authors:  Carrie L Byington; F Rene Enriquez; Charles Hoff; Richard Tuohy; E William Taggart; David R Hillyard; Karen C Carroll; John C Christenson
Journal:  Pediatrics       Date:  2004-06       Impact factor: 7.124

View more
  2 in total

1.  Community-acquired serious bacterial infections in the first 90 days of life: a revisit in the era of multi-drug-resistant organisms.

Authors:  Dawood Yusef; Tamara Jahmani; Sajeda Kailani; Rawan Al-Rawi; Wasim Khasawneh; Miral Almomani
Journal:  World J Pediatr       Date:  2019-06-22       Impact factor: 2.764

2.  Clinical Characteristics, Medication Prescription Pattern, and Treatment Outcomes at the Neonatal Intensive Care Unit of a Tertiary Health-Care Facility in Ghana.

Authors:  Kwame Opare-Asamoah; George Asumeng Koffuor; Alhassan Abdul-Mumin; Baba Mohammed Sulemana; Majeed Saeed; Lawrence Quaye
Journal:  J Res Pharm Pract       Date:  2021-05-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.